Jan 6, 2021 | Uncategorized
nn2021 has brought on new CPT changes and they’re not just in E/M. We’ve compiled a list of 30 FAQ’s so that you can start your 2021 E/M office and other outpatient visit reporting off right. Continue reading below for the top 5 FAQ’s or click here for the complete list! nnBy Ginger Avery, CPC, CPMA, CRCnJanuary 5, 2021nn1.Where can the CPT E/M code and guidelines be found? The CPT E/M code and guideline changes for 2021 can not only be found on the American Medical Associations (AMA) site at this link, but they can also be found in their entirety within the 2021 CPT Code books themselves. These guidelines include the new level of medical decision-making table and the 22 new definitions that help clarify what the MDM terms mean.nn2.Does pulling the lab results into the note constitute a “review of results” or do I need to document by stating that I have reviewed them? Moving forward information from old notes without comment does not add any value to the work that was performed and does not count. Did you review/analyze these results, what impact does this have on today’s visit? What is the clinical significance of this additional work?nn3.When tests are ordered during one visit and reviewed the same test during the next visit, can that count as a data point for both visits? With the new guidelines, we no longer have data “points”. Both encounters would support Limited data (low) with Category 1. The first encounter supports Category 1 for ordering of the test, the follow up encounter would support Category 1 for review of the results.nn4.Where does lifestyle counseling come into this? Preventive medicine counseling and/or risk factor reduction interventions (99401-99412) are time-based codes but do NOT follow the office visit E/M guidelines. Relevant visit details and total F2F time should be documented appropriately. Code selection is based on the F2F time spent with the patient.nn5.When reporting for total time, is it just time spent with patient at the encounter? No, in 2021, time is defined as the total encounter time on the date of service. This includes both F2F work and non-F2F work personally performed by the clinician.nnAs a reminder, documentation is about painting a clear picture of today’s encounter. The power of storytelling is evident with these new revisions. Quality documentation (not quantity or checkboxes) provides details to support the medical necessity and appropriate complexity of each unique encounter, as well as improves overall patient care and clinical outcomes. Clinicians are encouraged to focus their energy and documentation on the cognitive clinically relevant details, regardless of the clinical setting. Document what you do, code what you document.nn Welter Healthcare Partners provides robust coding and documentation training for these updates, as well as other topics. Please contact cwhitworth@rtwelter.com to book your training now.n
— CLICK TO VIEW THE COMPLETE LIST OF 30 FAQ’s TO START YOUR 2021 REPORTING OFF RIGHT —
nReferences:nAMA CPT® E/M Code and Guideline Changes for 2021nAma-assn.orgnNovitas E/M Documentation RequirementsnNoridian E/M Documentation Requirements
Dec 21, 2020 | Uncategorized
From our Welter Healthcare Partners family to yours, we hope you all have a merry holiday season and a safe, healthy, and happy New Year! We are grateful for the support and appreciation for the work that we do and are excited to continue in 2021!nnIn observance of the holidays, Welter Healthcare Partners will be closing at noon on December 24th and will be closed all day on December 25th and January 1st to spend time with our loved ones. Once again, happy holidays to you all and we hope you all have a great and prosperous New Year!nn
Dec 18, 2020 | Uncategorized
CMS updated payment information for Covid-19 treatments. This new update includes the reimbursement of monoclonal antibody treatments authorized by the FDA. Continue reading below to learn more.nnMonoclonal antibody products are paid under the Medicare Part B COVID-19 vaccine benefit and therefore are not eligible for a New COVID-19 Treatments Add-on Payment. CMS released new and updated FAQs on Medicare Part B billing and reimbursement for COVID-19 treatments and vaccines. The information updated December 9 is included in Section BB, Drugs and Vaccines under Part B of CMS’ COVID-19 billing FAQs.nnFor the duration of the public health emergency, CMS will pay for monoclonal antibody treatments authorized or approved by the FDA. For payment purposes, CMS is treating these products as vaccines covered under Medicare Part B. If the product is acquired for free, CMS will only pay for the administration. If the provider or supplier purchases the product, CMS will pay for the product and the administration separately. Monoclonal antibody products are paid under the Medicare Part B COVID-19 vaccine benefit and therefore are not eligible for a New COVID-19 Treatments Add-on Payment.nnPayment for administration of an infusion of bamlanivimab or an infusion of casirivimab and imdevimad is approximately $310. The payment rate is based on one hour of infusion and post-infusion monitoring in the hospital outpatient setting. CMS may change the payment rate based on additional information from providers and suppliers. When organizations begin purchasing monoclonal antibody products, CMS plans to set the payment rate in the same way it will set the payment rate for COVID-19 vaccines. The payment rate will be reasonable cost or 95% of the average wholesale price. A chart on p. 123 of the FAQ document shows payments rates by setting.nnCurrently, there is no separate payment for preparation of monoclonal antibodies, even if prepared for another provider or supplier. Monoclonal antibody products administered at a nonexcepted off-campus, provider-based department (PBD) will be paid at the full Outpatient Prospective Payment System (OPPS) rate. They will not be subject to the reduced rate (40% of the OPPS) that applies to other services provided at these facilities.nnDocumentation must support the medical necessity of the treatment as well as demonstrate that the terms of the applicable FDA emergency use authorization are met. The documentation must include the name of the practitioner who ordered the infusion.nnOther new and updated FAQs in Section BB include payment for monoclonal antibody treatment provided:n
n
- By skilled nursing facilities, mass immunizers, and home health agencies
n
- On the same day as evaluation and management services
n
- To beneficiaries dually eligible for Medicare and Medicaid
n
nOriginal article published on healthleadersmedia.com
Dec 18, 2020 | Uncategorized
The report below describes a patient undergoing a right inguinal hernia operation. The entire procedure has been documented in detail, describing the step by step process used by doctors to carry out the surgery. Keep reading for more on how this procedure was performed.nnDo you have a complicated surgery case that needs help with coding? Welter Healthcare Partners would love to help! Please upload the operative note by clicking on the link below. Remember to remove ALL patient protected health information and organization identifiers. Welter Healthcare Partners will not use any medical records submitted in which PHI is not removed and protected. nn– Click Here to Submit Redacted Surgery Case Study –nnPATIENT NAME: D., M.nnMR#: XXXXXnnSURGEON: T. G., M.D.nnDATE: 09/XX/2020nnPREOPERATIVE DIAGNOSES: Right inguinal hernia (direct), obesity.nnPOSTOPERATIVE DIAGNOSES: Right inguinal hernia (direct), obesity.nnOPERATIONS: Right inguinal hernia repair with mesh, excision of round ligamentnnSURGICAL ASSISTANT: J. D., SA-C.nnANESTHESIA: General endotracheal.nnESTIMATED BLOOD LOSS: Minimal.nnSPECIMEN REMOVED: Round ligament.n
INDICATION FOR SURGERY:
nThis is a 65-year-old female with a history of obesity, who has pain and bulge in the right groin consistent with inguinal hernia. The need for surgery and all the possible risks and complications were discussed at length with the patient with the help of the daughter, who helped with the translation. the patient understood, all the questions were answered, and she wanted to proceed with surgery.n
DESCRIPTION OF PROCEDURE:
nThe patient was brought in the operating room and placed on the table in supine position. After the general anesthesia was administered, the right groin and abdomen were prepped and draped in the usual sterile fashion.nnA slightly oblique incision was done in the right groin and deepened through the subcutaneous tissue. In the lower part of the inguinal area, the bulge of the inguinal hernia was identified. 11ie skin flaps were dissected. Good exposure of the fascia of external oblique muscle was obtained. 111e fascia was opened, and the inguinal canal was entered. 11ie patient had a quite very large bulging of the posterior wall of the inguinal cru1al consistent with a direct hernia. The round ligament was carefully divided between ligatures ru1d excised. A purse-string was placed in the fascia of the transversalis around the neck of the hernia and the bulging direct hernia was invaginated and the purse-string was tied. This repair was done with a O silk. At this point, the posterior wall of the inguinal canal was reinforced with a 2 x 4 Marlex mesh. The mesh was secured in place with 2 rows of continuous running 0 Prolene, suturing 1 margin of the mesh to the inguinal canal and the other margin of the mesh to the conjoint tendon and lateral margin of the rectus abdominis muscle fascia. 11ie fascia of the external oblique muscle was closed on top of the mesh with continuous running 0 Vicryl. The wound was irrigated with antibiotic solution. Perfect hemostasis was noted. Local anesthesia was injected. The wound was closed with continuous running 2-0 Vicryl in 2 layers for the subcutaneous tissue and continuous running 4-0 Monocryl subcuticular closure for the skin. Steri-Strips and sterile dressing were applied. The patient tolerated the procedure well and left the operating room in stable condition.
Dec 8, 2020 | Uncategorized
Medicare released a physician fee schedule on December 1st that is set to take effect on January 1st, 2020. The release of the Final Rule delivers a 10.2% drop in the Conversion Factor. Most other E/M revisions remain on track with the AMA. Continue reading below to learn more.nnby: Ginger Avery, CPC, CPMA, CRC 12/2/2020nAccording to the 2021 Medicare physician fee schedule released on December 1st , starting Jan. 1, 2021, clinicians are facing a 10.2% drop in the Medicare conversion factor, finalized at $32.41. This CF decrease will result in an up-and-down projection in 2021 for medical specialties. CMS states the cut is needed as a counterweight to the increased fees for E/M officenvisit codes (99202-99215), which account for 20% of fee schedule spending.n
Source: Final 2021 Medicare physician fee schedule, released Dec. 1
nThe final rule confirms that CMS has adopted relative value units (RVU) approved by the AMA. The new valuations boost total RVUs for nearly all of the office visit codes and elevate RVUs for established office codes 99212-99215 by an average of 28%.nnDue to the CF reduction, office visit codes will see a diminished payment increase in 2021. For example, reimbursement for new patient E/M codes 99202-99204 will be reduced. Established office visit codes will see an increase in the range of 11% to 15%. Coding patterns are expected to shift to higher levels of service based on the new guidelines.n
Source: Final 2021 Medicare physician fee schedule
nAccording to data contained in the final fee schedule, specialties that will see a positive outcome with the new CF includes: endocrinology (+16%), rheumatology (+15%), hematology/oncology (+14%) and family practice (+13%). Specialties that are on pace for pay cuts include radiology (-10%), chiropractor (-10%), nurse anesthetist (-10%) and physical and occupational therapy (-9%).nnIn 2021, either medical decision-making (MDM) or time will drive code selection for E/M office visit codes. Medically appropriate history and/or exam will be the new accepted practice. CMS states. “We continue to believe these policies will further our ongoing effort to reduce administrative burden, improve payment accuracy, and update the O/O E/M visit code set to better reflect the current practice of medicine.”nnCMS Replaces Prolonged Service Code 99417 with HCPCS Code G2212nCMS made the decision to issue a new HCPCS code, G2212, instead of 99417, for prolonged services when reporting based on time. As expected, CMS did not agree with the AMA’s final descriptor for 99417, and is requiring the visit to exceed the maximum time for 99205 and 99215 to be met before capturing G2212 , unlike AMA’s guidance to meet the minimum time before capturing prolonged service time.nnThe descriptor for Medicare’s new prolonged services code G2212: “Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (List separately in addition to CPT codes 99205, 99215 for office or other outpatient evaluation and management services) (Do not report G2212 on the same date of service as 99354, 99355, 99358, 99359, 99415, 99416). (Do not report G2212 for any time unit less than 15 minutes).”nnCheck with your commercial/private payers that may prefer the G code. Reach out to your software vendors to assure your systems are ready to capture these new codes. If your organization has not received training on the upcoming changes for E/M office visits services, now is the time, contact WHP for details.nnVisit Complexity Add-on HCPCS Code G2211 Enters the Coding ArenanAlthough it is not yet clear as to appropriate application, CMS will roll out add on code +G2211 (Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient’s single, serious condition or a complex condition. CMS stated in the final rule that the new add-on code will be appropriate for 90% of E/M office visit encounters and is appropriate for both new and established patients.nnTelehealth Rule Changes During/After COVIDnCMS finalized 114 Category 2 codes for telehealth – i.e., codes cleared for use outside of the restrictive distant-and-originating-site requirements and eligible for other flexibilities under the public health emergency (PHE). The agency also added a new “Category 3” of codes that “will remain on the list through the calendar year in which the PHE ends.” The bad news is these codes will eventually go back to the old telehealth rules if Congress does not change the law.nnCMS states it will conduct “a commissioned study, analysis of Medicare claims data or another assessment mechanism, to further study the impacts of this limited permanent expansion of the virtual presence policy to inform potential future rulemaking, and in an effort to prevent possible fraud, waste and abuse.”nnTelephone Visits New G codenCMS finalized its decision to cease separate payment for CPT telephone E/M codes 99441-99443 once the PHE ends. For the remainder of 2021, CMS created an interim code, G2252, for a “brief communication technology-based service (e.g., virtual check-in)” for established patients only. The code is priced at the same amount as CPT telephone visit code 99442 and covers 11-20-minute “medical discussion,”.nnCMS states that the G2252 service applies when a patient reports an exacerbation of an ongoing problem and wants to know whether a face-to-face office visit is warranted. CMS does not consider a telephone visit to be a substitute for an E/M service but instead “an assessment to determine the need for one.”nnCode G2252 will therefore be considered a communications technology-based service (CTBS) similar to a virtual check-in, not a telehealth service. Like the CPT phone codes, it will not be separately reported if the call occurs within seven days after a previous in-person visit or within 24 hours “or soonest available appointment.”nnRemote Patient MonitoringnCMS also finalized PHE flexibilities in remote patient monitoring codes: For example, while “only physicians and NPPs [non-physician providers] who are eligible to furnish E/M services may bill RPM services,” auxiliary personnel, including contract employees, may provide RPM services incident to under codes 99453 and 99454. Once the PHE ends, many of the current flexibilities will, too: For example, established patient-physician relationship will once again be required to initiate RPM services.nnThe waiver for direct supervision of NPPs by a physician using real-time, interactive audio and video technology is cleared through “the latter of the end of the calendar year in which the PHE ends or December 31, 2021.”nnCMS added some new virtual services that NPPs will be eligible to provide G2250 (Remote assessment of recorded video and/or images submitted by an established patient) and G2251 (Brief communication technology-based service, e.g. virtual check-in, by a qualified health care professional) for providers that cannot bill E/M services.nnTransitional Care ManagementnAs part of its ongoing quest to boost utilization of transitional care services (99495-99496), CMS is unbundling 14 end-stage renal disease (ESRD) codes and chronic care management (CCM) code G2058 – which will be replaced with 99439 next year – from the service.nnThis is a breaking news story. Please check CMS for additional updatesnnSee DecisionHealth’s Blog for more details.
